We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Icosavax (ICVX) Up 112% on Upbeat Data From RSV Jab Study
Read MoreHide Full Article
Shares of Icosavax were up 112.4% on Dec 14 after management announced positive six-month immunogenicity data from a phase I/Ib study. The study evaluated IVX-121, its respiratory syncytial virus (RSV) vaccine candidate, in adults aged 18 years and older.
Data from the study showed that a single dose administration of IVX-121 (without adjuvant) generated a sustained neutralizing antibody (nAb) response against RSV, which lasted for at least six months. The geometric mean titers (GMTs) against RSV-A at day 180 were maintained at 64-98% of the GMTs reported at day 28 in older adults. The pattern of durability for the RSV vaccine was also comparable in both young and older adult groups.
Though the GMTs for RSV-B showed greater variability, they were maintained above baseline through day 180.
The rise in share price was attributable to better-than-expected results from the phase I/Ib study. Investors cheered the news as the GMTs maintained at 64-98% appeared to be better than its competitors like Pfizer (PFE - Free Report) and GSK (GSK - Free Report) , whose RSV vaccine candidates are currently under FDA review.
In the year so far, Icosavax’s stock has lost 61.0% compared with the industry’s 17.6% decline.
Image Source: Zacks Investment Research
The phase I portion of the study evaluated the RSV vaccine in younger adults aged 18 through 45 years, while the phase Ib portion of the study evaluated the RSV vaccine in older adults aged 60 through 75 years. The study evaluated the RSV vaccine at three different dose levels — 25-µg, 75-µg and 250-µg.
The vaccine was reported safe and durable across both age groups and participants who received IVX-121 did not report any serious adverse events.
Icosavax plans to present additional data from the above study at a future medical meeting. Management also intends to report the 12-month immunogenicity data from the phase Ib portion of the study in mid-2023.
Earlier this month, Pfizer announced that its regulatory filing with the FDA seeking approval for its RSV vaccine candidate, RSVpreF, was granted priority review by the FDA. Pfizer’s filing seeks a review for the use of RSVpreF in older adults aged at least 60 years for the prevention of lower respiratory tract disease (LRTI). A final FDA decision on Pfizer’s RSV vaccine is expected by May 2023.
RSVPreF3, GSK’s RSV vaccine for older adults, is also under FDA priority review, with a decision expected in May 2023. Regulatory applications seeking approval of GSK’s RSV vaccine are under review in Japan and Europe as well.
Currently, there are no FDA-approved vaccines against RSV infections. If approved, either Pfizer or GSK’s vaccines may be the first approved RSV vaccine in the United States. Older adults are at maximum risk of getting RSV disease.
Apart from IVX-121, Icosavax is also evaluating IVX-A12, a bivalent vaccine that combines IVX-121 for RSV and IVX-241 for human metapneumovirus (hMPV), in an ongoing phase I study. With IVX-A12, Icosavax aims to target two causes of pneumonia in one combination. Topline data from this study is expected in mid-2023.
In the past 30 days, estimates for BioNTech’s 2022 earnings per share have risen from $34.47 to $35.38. During the same period, the loss estimates per share for 2023 have narrowed from $16.97 to $17.53. Shares of BioNTech have lost 27.8% in the year-to-date period.
Earnings of BioNTech beat estimates in three of the last four quarters and missed the mark once, witnessing a surprise of 58.99% on average. In the last reported quarter, BNTX delivered an earnings surprise of 92.35%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Icosavax (ICVX) Up 112% on Upbeat Data From RSV Jab Study
Shares of Icosavax were up 112.4% on Dec 14 after management announced positive six-month immunogenicity data from a phase I/Ib study. The study evaluated IVX-121, its respiratory syncytial virus (RSV) vaccine candidate, in adults aged 18 years and older.
Data from the study showed that a single dose administration of IVX-121 (without adjuvant) generated a sustained neutralizing antibody (nAb) response against RSV, which lasted for at least six months. The geometric mean titers (GMTs) against RSV-A at day 180 were maintained at 64-98% of the GMTs reported at day 28 in older adults. The pattern of durability for the RSV vaccine was also comparable in both young and older adult groups.
Though the GMTs for RSV-B showed greater variability, they were maintained above baseline through day 180.
The rise in share price was attributable to better-than-expected results from the phase I/Ib study. Investors cheered the news as the GMTs maintained at 64-98% appeared to be better than its competitors like Pfizer (PFE - Free Report) and GSK (GSK - Free Report) , whose RSV vaccine candidates are currently under FDA review.
In the year so far, Icosavax’s stock has lost 61.0% compared with the industry’s 17.6% decline.
Image Source: Zacks Investment Research
The phase I portion of the study evaluated the RSV vaccine in younger adults aged 18 through 45 years, while the phase Ib portion of the study evaluated the RSV vaccine in older adults aged 60 through 75 years. The study evaluated the RSV vaccine at three different dose levels — 25-µg, 75-µg and 250-µg.
The vaccine was reported safe and durable across both age groups and participants who received IVX-121 did not report any serious adverse events.
Icosavax plans to present additional data from the above study at a future medical meeting. Management also intends to report the 12-month immunogenicity data from the phase Ib portion of the study in mid-2023.
Earlier this month, Pfizer announced that its regulatory filing with the FDA seeking approval for its RSV vaccine candidate, RSVpreF, was granted priority review by the FDA. Pfizer’s filing seeks a review for the use of RSVpreF in older adults aged at least 60 years for the prevention of lower respiratory tract disease (LRTI). A final FDA decision on Pfizer’s RSV vaccine is expected by May 2023.
RSVPreF3, GSK’s RSV vaccine for older adults, is also under FDA priority review, with a decision expected in May 2023. Regulatory applications seeking approval of GSK’s RSV vaccine are under review in Japan and Europe as well.
Currently, there are no FDA-approved vaccines against RSV infections. If approved, either Pfizer or GSK’s vaccines may be the first approved RSV vaccine in the United States. Older adults are at maximum risk of getting RSV disease.
Apart from IVX-121, Icosavax is also evaluating IVX-A12, a bivalent vaccine that combines IVX-121 for RSV and IVX-241 for human metapneumovirus (hMPV), in an ongoing phase I study. With IVX-A12, Icosavax aims to target two causes of pneumonia in one combination. Topline data from this study is expected in mid-2023.
Icosavax, Inc. Price
Icosavax, Inc. price | Icosavax, Inc. Quote
Zacks Rank & Stocks to Consider
Icosavax currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the overall healthcare sector is BioNTech (BNTX - Free Report) which carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 30 days, estimates for BioNTech’s 2022 earnings per share have risen from $34.47 to $35.38. During the same period, the loss estimates per share for 2023 have narrowed from $16.97 to $17.53. Shares of BioNTech have lost 27.8% in the year-to-date period.
Earnings of BioNTech beat estimates in three of the last four quarters and missed the mark once, witnessing a surprise of 58.99% on average. In the last reported quarter, BNTX delivered an earnings surprise of 92.35%.